These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22170152)

  • 1. Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders.
    Graziotto JJ; Cao K; Collins FS; Krainc D
    Autophagy; 2012 Jan; 8(1):147-51. PubMed ID: 22170152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.
    Cao K; Graziotto JJ; Blair CD; Mazzulli JR; Erdos MR; Krainc D; Collins FS
    Sci Transl Med; 2011 Jun; 3(89):89ra58. PubMed ID: 21715679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases.
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2011 Aug; 14(4):437-41. PubMed ID: 21851176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype.
    Pellegrini C; Columbaro M; Capanni C; D'Apice MR; Cavallo C; Murdocca M; Lattanzi G; Squarzoni S
    Oncotarget; 2015 Oct; 6(30):29914-28. PubMed ID: 26359359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptide Y Enhances Progerin Clearance and Ameliorates the Senescent Phenotype of Human Hutchinson-Gilford Progeria Syndrome Cells.
    Aveleira CA; Ferreira-Marques M; Cortes L; Valero J; Pereira D; Pereira de Almeida L; Cavadas C
    J Gerontol A Biol Sci Med Sci; 2020 May; 75(6):1073-1078. PubMed ID: 32012215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria.
    Cenni V; Capanni C; Columbaro M; Ortolani M; D'Apice MR; Novelli G; Fini M; Marmiroli S; Scarano E; Maraldi NM; Squarzoni S; Prencipe S; Lattanzi G
    Eur J Histochem; 2011 Oct; 55(4):e36. PubMed ID: 22297442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
    Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
    Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype.
    Gabriel D; Gordon LB; Djabali K
    PLoS One; 2016; 11(12):e0168988. PubMed ID: 28033363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
    Finley J
    Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome.
    Liu GH; Barkho BZ; Ruiz S; Diep D; Qu J; Yang SL; Panopoulos AD; Suzuki K; Kurian L; Walsh C; Thompson J; Boue S; Fung HL; Sancho-Martinez I; Zhang K; Yates J; Izpisua Belmonte JC
    Nature; 2011 Apr; 472(7342):221-5. PubMed ID: 21346760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
    Gabriel D; Roedl D; Gordon LB; Djabali K
    Aging Cell; 2015 Feb; 14(1):78-91. PubMed ID: 25510262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.
    Harhouri K; Frankel D; Bartoli C; Roll P; De Sandre-Giovannoli A; Lévy N
    Nucleus; 2018 Jan; 9(1):246-257. PubMed ID: 29619863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESCRT-III controls nuclear envelope deformation induced by progerin.
    Arii J; Maeda F; Maruzuru Y; Koyanagi N; Kato A; Mori Y; Kawaguchi Y
    Sci Rep; 2020 Nov; 10(1):18877. PubMed ID: 33139753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated image analysis of nuclear shape: what can we learn from a prematurely aged cell?
    Driscoll MK; Albanese JL; Xiong ZM; Mailman M; Losert W; Cao K
    Aging (Albany NY); 2012 Feb; 4(2):119-32. PubMed ID: 22354768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
    Wang Y; Ostlund C; Worman HJ
    Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hutchinson-Gilford progeria syndrome through the lens of transcription.
    Prokocimer M; Barkan R; Gruenbaum Y
    Aging Cell; 2013 Aug; 12(4):533-43. PubMed ID: 23496208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
    Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
    Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hutchinson-Gilford progeria syndrome, cardiovascular disease and oxidative stress.
    Trigueros-Motos L; Gonzalez JM; Rivera J; Andres V
    Front Biosci (Schol Ed); 2011 Jun; 3(4):1285-97. PubMed ID: 21622271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.
    Arancio W; Pizzolanti G; Genovese SI; Pitrone M; Giordano C
    Gerontology; 2014; 60(3):197-203. PubMed ID: 24603298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment.
    Columbaro M; Capanni C; Mattioli E; Novelli G; Parnaik VK; Squarzoni S; Maraldi NM; Lattanzi G
    Cell Mol Life Sci; 2005 Nov; 62(22):2669-78. PubMed ID: 16261260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.